TEL AVIV, Israel, December 4, 2012 /PRNewswire/ --
Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today that on December 3, 2012, Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M) (in which the Company holds approximately 90%), announced that InSightec Ltd. ("InSightec") (in which Elbit Medical holds approximately 64%, and 52.15% on a fully diluted basis) has been awarded the European CE mark for its transcranial focused ultrasound system, ExAblate Neuro, with respect to the treatment of neurological disorders in the brain, including essential tremor, Parkinson's disease and neuropathic pain.
Treatment options for patients suffering from neurological disorders, who do not respond to drug treatments include deep brain stimulation, radiofrequency ablation and radiosurgery, which are invasive or involve ionizing radiation and are associated with recognized radiation risks and high risk of complications and side effects. As opposed to the above, InSightec elaborated, ExAblate® Neuro offers a non-invasive treatment with no ionizing radiation by treating tissue deep in the brain through an intact skull. MR guided Focused ultrasound (MRgFUS) combines therapeutic acoustic ultrasound waves with continuous MRI guidance. The MRI enables physicians to visualize, plan, guide, monitor and control the treatment, while the ultrasound acoustic energy destroys the targeted tissue in the brain. InSightec recently received its second ExAblate FDA approval for the treatment of painful bone metastases in patients who are unable or unwilling to undergo radiation. This is in addition to FDA approval for uterine fibroids received in 2004.
InSightec Ltd. is privately held by Elbit Imaging, General Electric, and MediTech Advisors. Founded in 1999, InSightec developed ExAblate to transform MRI-guided Focus